Pharmacoeconomic Study of Herceptin® (Trastuzumab) for Breast Cancer Patients

Pharmacoeconomics: theory and practice
doi 10.30809/phe.4.2014.4
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Moscow Pharmaceutical Society

Related search

Trastuzumab (Herceptin)

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2011English

Safety of Trastuzumab (Herceptin®) During Pregnancy: Two Case Reports

Cases Journal
2009English

Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections

Journal of Histochemistry and Cytochemistry
AnatomyHistology
2006English

Substituting Adjuvant Trastuzumab Emtansine for Herceptin Improves Survival in Patients With Human Epidermal Growth Factor Receptor 2–positive Breast Cancer

Cancer
Cancer ResearchOncology
2019English

Comparative Nonclinical Assessments of the Proposed Biosimilar PF-05280014 and Trastuzumab (Herceptin®)

BioDrugs
MedicineBiotechnologyPharmacology
2014English

Pcn103 - Predicted Treatment Costs and Savings Per Patient of Kanjinti® (Trastuzumab Biosimilar) vs. Subcutaneous (Sc) and Intravenous (Iv) Herceptin® and Other Trastuzumab Biosimilars in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Trastuzumab-Containing Regimens for Metastatic Breast Cancer

Cochrane Database of Systematic Reviews
2014English

Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

The Evaluation of Left Ventricular Function for Patients Being Considered For, or Receiving Trastuzumab (Herceptin) Therapy

British Journal of Cancer
Cancer ResearchOncology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy